| Followers | 9888 |
| Posts | 261364 |
| Boards Moderated | 4 |
| Alias Born | 12/27/2006 |
Friday, May 08, 2020 6:32:12 PM
* * $VSTM Video Chart 05-08-2020 * *
Link to Video - click here to watch the technical chart video
Link to Video - click here to watch the technical chart video
Recent VSTM News
- Verastem Oncology Announces Two-Year Median Follow-Up Data on AVMAPKI® FAKZYNJA® Combination Therapy (avutometinib capsules; defactinib tablets) in Recurrent Low-Grade Serous Ovarian Cancer at the SGO 2026 Annual Meeting on Women’s Cancers • Business Wire • 04/10/2026 11:00:00 AM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/09/2026 08:14:51 PM
- Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • Business Wire • 04/02/2026 08:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/23/2026 09:20:14 PM
- Verastem Oncology Announces Late Breaking and Regular Abstracts Accepted for Presentation at the AACR Annual Meeting 2026 • Business Wire • 03/17/2026 10:03:00 PM
- Verastem Oncology Announces Abstracts Accepted for Presentation on AVMAPKI™ FAKZYNJA™ (avutometinib capsules; defactinib tablets) Combination Therapy at the Society of Gynecologic Oncology 2026 Annual Meeting on Women’s Cancers • Business Wire • 03/17/2026 08:44:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/04/2026 09:15:33 PM
- Verastem Oncology Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Business Updates • Business Wire • 03/04/2026 09:01:00 PM
- Verastem Oncology to Report Fourth Quarter and Full Year 2025 Financial Results on March 4, 2026 • Business Wire • 02/18/2026 12:30:00 PM
- Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors • Edgar (US Regulatory) • 02/18/2026 02:43:02 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/05/2026 09:10:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/04/2026 12:30:33 PM
- Verastem Oncology Provides Preliminary Fourth Quarter and 2025 Revenue and Business Updates and Outlines 2026 Strategic Priorities for Novel Portfolio Targeting RAS/MAPK Pathway-Driven Cancers • Business Wire • 02/04/2026 12:30:00 PM
- $668B Oncology Surge: 5 Platforms Cracking the Code on GI Tumors • PR Newswire (US) • 01/30/2026 03:19:00 PM
- $668B Oncology Surge: 5 Platforms Cracking the Code on GI Tumors • PR Newswire (Canada) • 01/30/2026 03:19:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/23/2026 09:58:52 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/23/2026 09:57:26 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 01/14/2026 10:15:00 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 01/14/2026 10:13:42 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/14/2026 10:12:40 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/14/2026 10:11:29 PM
- Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • Business Wire • 01/12/2026 09:01:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/08/2026 09:16:07 PM
